$0.65
+0.00 (+0.62%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where TELA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional · 1 observational · 1 with posted results
Held by 2 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, JANE STREET GROUP, LLC) · FINRA short interest 10.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®NCT07070115Hernia recurrenceOpen-label · Treatment | Not applicable | Recruiting | Device: OviTex Reinforced Tissue Matrix | Hiatal Hernia | 173 | 2031-12-31 | in 1,959 d | 2026-08-18 |
| Effectiveness and Safety of OviTex® PRS in Breast ReconstructionNCT07135596Reconstructive Failure RateOpen-label · Treatment | Not applicable | Recruiting | Device: OviTex PRS | Breast Reconstruction | 235 | Jun 2030 | ≤ 1,410 d | 2026-06-02 |
| Ventral or Inguinal Hernia, Robotically Repaired With OviTex MeshNCT04779918Early surgical site occurrences or wound related eventsOpen-label · Treatment | Not applicable | Recruiting | Device: OviTex Reinforced Tissue Matrix | Hernia, Ventral, Hernia, Inguinal | 160 | 2027-03-30 | in 222 d | 2026-05-05 |
| A Retrospective Assessment of OviTex PRS (OviTex)NCT05736848observationalThe occurrence of relevant (S)AEs within 24 months of OviTex® PRS implantation. | — | Active, not recruiting | Device: OviTex® PRS | Reconstructive Surgical Procedures | 200 | 2026-08-30 | in 10 d | 2026-08-18 |
| Ventral Hernia Study Using OviTex Reinforced BioscaffoldNCT03074474results2023-06-13Surgical Site Occurrences or Wound-related EventsOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: OviTex 1S Permanent | Hernia, Ventral | 92 | 2019-12-08actual | — | 2023-06-13 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19